Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD7 CAR T cells PA3-17

A preparation of autologous T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous anti-CD7 CAR T cells PA3-17 specifically recognize and bind to CD7-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD7 is a transmembrane glycoprotein expressed by T cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CD7-CAR T cells PA3-17
autologous CD7-CAR T cells PA3-17
autologous CD7-targeted CAR T cells PA3-17
Code name:PA3 17
PA3-17
PA317
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search